These are all glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Tack J, Arts J, Caenepeel P, De Wulf D, Bisschops R
These criticisms include concerns that wealthy people are using expensive, previously scarce drugs and that influencers are promoting unrealistic expectations of the benefits
GLP-1RAs further lower the risk of stroke indirectly by reducing traditional stroke risk factors such as HbA1c, SBP, body weight, and dyslipidemia
Raben, M
* Correspondence: Pablo Albertos, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers